|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
11,270,000 |
Market
Cap: |
270.25(M) |
Last
Volume: |
197,427 |
Avg
Vol: |
196,888 |
52
Week Range: |
$13.82 - $26.5 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
5,250 |
117,800 |
Total Buy Value |
$0 |
$0 |
$74,754 |
$2,088,813 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
5 |
21 |
Total Shares Sold |
0 |
0 |
0 |
27,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bowes William K Jr |
Director |
|
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
21,268 |
|
- |
|
Walbert Timothy P |
Director |
|
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
20,197 |
|
- |
|
Wyszomierski Jack L |
Director |
|
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
20,197 |
|
- |
|
Van Ness W Denman |
Director |
|
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,450 |
26,352 |
|
- |
|
Varian John |
CEO |
|
2014-05-15 |
4 |
AS |
$3.55 |
$35,515 |
D/D |
(10,000) |
285,613 |
|
- |
|
Varian John |
CEO |
|
2014-05-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
295,613 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-05-13 |
4 |
S |
$3.84 |
$38,404 |
D/D |
(10,000) |
80,719 |
|
- |
|
Varian John |
CEO |
|
2014-04-15 |
4 |
AS |
$4.06 |
$40,645 |
D/D |
(10,000) |
285,613 |
|
- |
|
Varian John |
CEO |
|
2014-04-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
295,613 |
|
- |
|
Neal James R |
VP Business Development |
|
2014-03-31 |
5 |
A |
$4.95 |
$6,083 |
D/D |
1,229 |
152,670 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-03-31 |
5 |
A |
$4.95 |
$5,514 |
D/D |
1,114 |
94,608 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2014-03-18 |
4 |
S |
$6.32 |
$37,359 |
D/D |
(5,915) |
62,600 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2014-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,875 |
68,515 |
|
- |
|
Klein Thomas |
Chief Commercial Officer |
|
2014-03-18 |
4 |
S |
$6.32 |
$195,575 |
D/D |
(30,965) |
93,150 |
|
- |
|
Klein Thomas |
Chief Commercial Officer |
|
2014-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
80,667 |
123,858 |
|
- |
|
Neal James R |
VP Business Development |
|
2014-03-18 |
4 |
S |
$6.32 |
$16,870 |
D/D |
(2,671) |
151,441 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2014-03-18 |
4 |
S |
$6.32 |
$21,594 |
D/D |
(3,419) |
91,546 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2014-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,500 |
94,965 |
|
- |
|
Varian John |
CEO |
|
2014-03-18 |
4 |
S |
$6.32 |
$134,714 |
D/D |
(21,329) |
285,613 |
|
- |
|
Varian John |
CEO |
|
2014-03-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,907 |
306,942 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-03-18 |
4 |
AS |
$6.31 |
$111,423 |
D/D |
(17,649) |
90,719 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-03-18 |
4 |
OE |
$0.00 |
$18,240 |
D/D |
36,347 |
96,719 |
|
- |
|
Varian John |
CEO |
|
2014-03-17 |
4 |
AS |
$6.03 |
$60,292 |
D/D |
(10,000) |
270,035 |
|
- |
|
Varian John |
CEO |
|
2014-03-17 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
280,035 |
|
- |
|
Limber Joseph M |
Director |
|
2014-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,600 |
5,600 |
|
- |
|
597 Records found
|
|
Page 15 of 24 |
|
|